← Leaderboards
Smita Bhatia
University Of Southern California
$27,398,641
Attributed
$28,970,285
Total exposure
25
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$28,970,285 · 25
By mechanism
R01$11,111,504 · 5
U01$6,841,988 · 1
R35$5,874,754 · 1
P50$2,900,189 · 1
M01$1,320,787 · 15
P01$921,063 · 2
Top collaborators
- Wendy Landier5 shared
Most similar at University Of Southern California
Same institution · by research overlap
- Krishna S Nayak$6,675,689
Others in their field
Top investigators on “Cohort”
- David R. Weir · University Of Michigan At Ann Arbor$406,814,098
- George R Seage · Abt Associates, Inc.$297,656,361
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$242,146,554
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
- Lawrence Corey · Fred Hutchinson Cancer Center$227,738,417
- James Dennis Neaton · Northwestern University$203,539,316
Research focus
CohortFutureIncidenceMalignant NeoplasmsHigh RiskPathogenesisChronicGenetic Predisposition To DiseaseLifeRadiationMalignant Childhood NeoplasmResearch PersonnelFundingDiagnosisGeneticChemotherapyDoseSurvivorsResourcesBaseTransplantationMorbidity - Disease RateIndexingCities
Grant awards (71)
Mitigating Long-term Treatment-related Morbidity in Childhood Cancer Survivors$808,678
R35 · FY2024 · CA · contact PI
BMT Survivor Study-2 (BMTSS-2)$1,266,852
U01 · FY2023 · CA · contact PI
Mitigating Long-term Treatment-related Morbidity in Childhood Cancer Survivors$868,290
R35 · FY2023 · CA · contact PI
BMT Survivor Study-2 (BMTSS-2)$1,254,755
U01 · FY2022 · CA · contact PI
Mitigating Long-term Treatment-related Morbidity in Childhood Cancer Survivors$875,950
R35 · FY2022 · CA · contact PI
Therapy-related leukemia following autologous transplantation for lymphoma$409,866
P50 · FY2022 · CA · contact PI
BMT Survivor Study-2 (BMTSS-2)$1,290,138
U01 · FY2021 · CA · contact PI
Mitigating Long-term Treatment-related Morbidity in Childhood Cancer Survivors$828,233
R35 · FY2021 · CA · contact PI
Therapy-related leukemia following autologous transplantation for lymphoma$604,943
P50 · FY2021 · CA · contact PI
BMT Survivor Study-2 (BMTSS-2)$1,569,615
U01 · FY2020 · CA · contact PI
Mitigating Long-term Treatment-related Morbidity in Childhood Cancer Survivors$819,621
R35 · FY2020 · CA · contact PI
Therapy-related leukemia following autologous transplantation for lymphoma$638,056
P50 · FY2020 · CA · contact PI
BMT Survivor Study-2 (BMTSS-2)$148,500
U01 · FY2020 · CA · contact PI
BMT Survivor Study-2 (BMTSS-2)$1,312,128
U01 · FY2019 · CA · contact PI
Mitigating Long-term Treatment-related Morbidity in Childhood Cancer Survivors$806,311
R35 · FY2019 · CA · contact PI
Therapy-related leukemia following autologous transplantation for lymphoma$570,915
P50 · FY2019 · CA · contact PI
Mitigating Long-term Treatment-related Morbidity in Childhood Cancer Survivors$867,671
R35 · FY2018 · CA · contact PI
Therapy-related leukemia following autologous transplantation for lymphoma$676,409
P50 · FY2018 · CA · contact PI
Comprehensive Approach to Improve Medicine Adherence in Pediatric Leukmia$597,219
R01 · FY2018 · CA · contact PI
Comprehensive Approach to Improve Medicine Adherence in Pediatric Leukmia$606,475
R01 · FY2017 · CA · contact PI
Comprehensive Approach to Improve Medicine Adherence in Pediatric Leukmia$620,968
R01 · FY2016 · CA · contact PI
Comprehensive Approach to Improve Medicine Adherence in Pediatric Leukmia$570,751
R01 · FY2015 · CA · contact PI
Comprehensive Approach to Improve Medicine Adherence in Pediatric Leukemia$747,876
R01 · FY2014 · CA · contact PI
Role of Genetic Susceptibility in Therapy-related Subsequent Malignancies$470,514
R01 · FY2014 · CA · contact PI
Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction$348,987
R01 · FY2014 · CA · contact PI
Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction$170,134
R01 · FY2014 · CA · contact PI
Role of Genetic susceptibility in Therapy-related Subsequent Malignancies$89,068
R01 · FY2014 · CA · contact PI
Role of Genetic Susceptibility in Therapy-related Subsequent Malignancies$569,900
R01 · FY2013 · CA · contact PI
Role of Genetic Susceptibility in Therapy-related Subsequent Malignancies$634,757
R01 · FY2012 · CA · contact PI
Role of Genetic Susceptibility in Therapy-related Subsequent Malignancies$630,540
R01 · FY2011 · CA · contact PI
Role of Genetic Susceptibility in Therapy-related Subsequent Malignancies$708,614
R01 · FY2010 · CA · contact PI
Hematopoietic Cell Transplant - Long-term Follow-Up Core$216,006
P01 · FY2010 · CA · contact PI
LONG TERM FOLLOW-UP CLINIC FOR SURVIVORS OF CHILDHOOD CANCER AND PEDIATRIC HEMAT$311,902
M01 · FY2009 · RR · contact PI
Hematopoietic Cell Transplant - Long-term Follow-Up Core$201,870
P01 · FY2009 · CA · contact PI
Ethnic Differences in Survival after Childhood ALL$166,000
R01 · FY2009 · CA · contact PI
MOLECULAR PATHOGENESIS OF THERAPY RELATED LEUKEMIA$139,138
M01 · FY2009 · RR · contact PI
HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES$3,478
M01 · FY2009 · RR · contact PI
Ethnic Differences in Survival after Childhood ALL$488,086
R01 · FY2008 · CA · contact PI
LONG TERM FOLLOW-UP CLINIC FOR SURVIVORS OF CHILDHOOD CANCER AND PEDIATRIC HEMAT$228,329
M01 · FY2008 · RR · contact PI
MOLECULAR PATHOGENESIS OF THERAPY RELATED LEUKEMIA$200,691
M01 · FY2008 · RR · contact PI
Hematopoietic Cell Transplant - Long-term Follow-Up Core$195,238
P01 · FY2008 · CA · contact PI
KEY ADVERSE EVENTS AFTER CHILDHOOD CANCER$7,210
M01 · FY2008 · RR · contact PI
Ethnic Differences in Survival after Childhood ALL$485,753
R01 · FY2007 · CA · contact PI
Hematopoietic Cell Transplant - Long-term Follow-Up Core$195,523
P01 · FY2007 · CA · contact PI
MOLECULAR PATHOGENESIS OF THERAPY RELATED LEUKEMIA$156,028
M01 · FY2007 · RR · contact PI
KEY ADVERSE EVENTS AFTER CHILDHOOD CANCER$968
M01 · FY2007 · RR · contact PI
LONG TERM FOLLOW-UP CLINIC FOR SURVIVORS OF CHILDHOOD CANCER AND PEDIATRIC HEMAT$968
M01 · FY2007 · RR · contact PI
Ethnic Differences in Survival after Childhood ALL$508,100
R01 · FY2006 · CA · contact PI
MOLECULAR PATHOGENESIS OF THERAPY RELATED LEUKEMIA$150,239
M01 · FY2006 · RR · contact PI
Hematopoietic Cell Transplant - Long-term Follow-Up Core$112,426
P01 · FY2006 · CA · contact PI
LONG TERM FOLLOW-UP CLINIC FOR SURVIVORS OF CHILDHOOD CANCER AND PEDIATRIC$17,418
M01 · FY2006 · RR · contact PI
UNDERSTANDING THE ETHNIC AND RACIAL DIFFERENCES$3,266
M01 · FY2006 · RR · contact PI
KEY ADVERSE EVENTS AFTER CHILDHOOD CANCER$2,178
M01 · FY2006 · RR · contact PI
Ethnic Differences in Survival after Childhood ALL$523,875
R01 · FY2005 · CA
LONG TERM FOLLOW-UP CLINIC FOR SURVIVORS OF CHILDHOOD CANCER AND PEDIATRIC HEMAT$59,911
M01 · FY2005 · RR
MOLECULAR PATHOGENESIS OF THERAPY RELATED LEUKEMIA$10,329
M01 · FY2005 · RR
UNDERSTANDING THE ETHNIC AND RACIAL DIFFERENCES$3,099
M01 · FY2005 · RR
KEY ADVERSE EVENTS AFTER CHILDHOOD CANCER$1,032
M01 · FY2005 · RR
Ethnic Differences in Survival after Childhood ALL$532,508
R01 · FY2004 · CA
Molecular Pathogenesis of Therapy Related Leukemia$20,325
M01 · FY2004 · RR
Long Term Follow-Up Clinic for Survivors of Child Cancer$3,209
M01 · FY2004 · RR
Understanding the Ethnic and Racial Differences$1,069
M01 · FY2004 · RR
BONE MARROW TRANSPLANT (BMT) SURVIVORS STUDY$436,039
R01 · FY2003 · CA
BONE MARROW TRANSPLANT (BMT) SURVIVORS STUDY$383,314
R01 · FY2002 · CA
CORE--LONG TERM FOLLOWUP$0
P01 · FY2002 · CA
BONE MARROW TRANSPLANT (BMT) SURVIVORS STUDY$410,083
R01 · FY2001 · CA
CORE--LONG TERM FOLLOWUP$0
P01 · FY2001 · CA
BONE MARROW TRANSPLANT (BMT) SURVIVORS STUDY$411,943
R01 · FY2000 · CA
MOLECULAR PATHOGENESIS OF THERAPY RELATED LEUKEMIA$0
M01 · FY2000 · RR
CORE--LONG TERM FOLLOWUP$0
P01 · FY2000 · CA
MOLECULAR PATHOGENESIS OF THERAPY RELATED LEUKEMIA$0
M01 · FY2000 · RR